一、報告題目：Molecular Design between Chance and Necessity : a medicinal chemist’s daily life

二、報告時間：2024年4月22日（周一）下午15：30

三、報告地點：莫干山校區(qū)協(xié)同中心1A 203報告廳

四、主講人：Professor Benoit Deprez

五、主講人簡介

Professor of Chemistry, Faculty of Pharmacy, University of Lille. Founder and director of the Drugs and Molecules for living systems research unit. Vice-president of the Société deChimie Thérapeutique. After studying pharmacy in Lille, Benoit Deprez completed a doctorate in medicinal chemistry in André Tartar's laboratory at the Pasteur Institute in Lille (1997). With André Tartar, he set up the high throughput chemistry laboratory at the Pasteur Institute in Lille, which in 1997 became the chemistry department of Cerep (now Eurofins). In 1999, after 3 years at Cerep as Director of Chemistry and Director of the Lille site, he joined Devgen (now Syngenta), a Belgian start-up in Ghent (Flanders), where he set up drug discovery activities based on the biology of C.elegans, whose genome had just been sequenced. At the Institut Pasteur in Lille and in these two companies, he managed several collaborations between biotech or academic laboratories and pharmaceutical companies (GSK, Merck KGa, Sanofi, Genentech, Bioversys). Beno?t Deprez is currently Professor of Chemistry and Drug Discovery at the Lille Faculty of Pharmacy and founder and Director of U1177, based at the Pasteur Institute in Lille. His research focuses on the validation of new therapeutic targets, therapeutic chemistry and pharmacokinetics. Benoit is an elected member of the Académie Nationale de Pharmacie. He is vice-president of communications for the Société de Chimie Thérapeutique ( www.sct-asso.fr ). In 2013, he founded Apteeus with Terence Beghyn, a company specialising in personalised drug discovery for rare metabolic diseases. Two drug candidates discovered in his laboratory are currently licensed at the clinical development stage: a new chemical entity, a first in class antibacterial: alpibectir, and a repositioned molecule: clofoctol.

六、講座簡介

Medicinal chemists play a crucial role in drug discovery. They optimize drug candidates through a process of molecular evolution, creating variations (either biased or unbiased) and using a variety of disease models to select the best combinations of properties. In order to efficiently vary the molecular structure, a chemist must have a strong command of organic chemistry and a clear understanding of how to interact with the target. Equipping the molecule to cross physical and chemical barriers to reach the target site is also crucial. My presentation provides examples of drug optimization and strategies for conducting efficient research in the early stages of drug R&D.